Polymer-Protein Conjugates

Gianfranco Pasut

ISBN 10: 0444640819 / ISBN 13: 9780444640819

Edité par Elsevier Science & Technology Okt 2019, 2019

A propos de cet article

Neuware.

N° de réf. du vendeur 9780444640819

Détails bibliographiques

• Titre: Polymer-Protein Conjugates
• Éditeur: Elsevier Science & Technology Okt 2019
• Date de parution: 2019
• Langue: anglais
• ISBN à 10 chiffres: 0444640819
• ISBN à 13 chiffres: 9780444640819
• Reliure: Taschenbuch
• État de l'article: Neu
• Dimensions: 235 L x 191 H x 25 P (en millimètres) 235 millimètres de largeur par 191 millimètres de hauteur par 25 millimètres de profondeur
• Poids: 639 grammes

A propos de ce titre

Synopsis

Polymer-Protein Conjugates: From Pegylation and Beyond helps researchers by offering a unique reference and guide into this fascinating area. Sections cover the challenges surrounding the homogeneity of conjugates, their purity and polymer toxicity on long-term use, and how to deal with the risk of immunogenicity. These discussions help researchers design new projects by taking into account the latest innovations for safe and site selective polymer conjugation to proteins. PEG has been the gold standard and likely will play this role for many years, but alternatives are coming into the market, some of which have already been launched.

After five decades of improvements, the ideas in this book are entering into a new era of innovation because of the advances in genetic engineering, biochemistry and a better understanding of the results from clinical use of PEG conjugates in humans.

À propos des auteurs

Gianfranco Pasut, PhD is Full Professor of Pharmaceutical Technology at the University of Padua and has more than 20 years of research experience in the field of drug and protein delivery, in particular by polymer conjugation. He is an author of more than 70 peer-reviewed publications and 14 book chapters on polymer conjugation and an inventor of 9 patents. His research lab investigates new approaches of polymer conjugation, ADC and targeted liposome preparations and pioneered and expanded the use of the enzyme transglutaminase for the development of new conjugates.

Samuel Zalipsky, Ph.D. is currently an independent consultant in the areas of carrier mediated drug delivery, nanoparticles, biocompatible polymers, liposomes, preparation and applications of a wide spectrum of bioconjugates, and PEGylated biopharmaceuticals in particular. His professional tenure of over 30 years was spent mainly in pharmaceutical industry, contributing to several commercialized technologies and products. He is an author of over 90 publications and listed as an inventor on over 50 patents.